Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study.

doi:10.1200/JCO.2021.39.15_suppl.e19507

	Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study.
	Song, Yuqin ; Gao, Quanli ; Zhang, Huilai ; Fan, Lei ; Zhou, Jianfeng ; Zou, Dehui ; Li, Wei ; Yang, Haiyan ; Liu, Ting ; Wang, Quanshun
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2021-05-20
卷号	39
ISSN号	0732-183X
DOI	10.1200/JCO.2021.39.15_suppl.e19507
资助项目	BeiGene (Beijing) Co., Ltd
WOS研究方向	Oncology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000708120304144
资助机构	BeiGene (Beijing) Co., Ltd
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/126670]
专题	中国科学院合肥物质科学研究院
作者单位	1.Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China 2.Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China 3.BeiGene Beijing Co Ltd, Beijing, Peoples R China 4.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Lymphoma, Hangzhou, Peoples R China 5.Jilin Univ, Hosp 1, Canc Ctr, Dept Hematol, Changchun, Peoples R China 6.Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China 7.Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China 8.Tongji Med Coll, Tongji Hosp, Dept Hematol, Wuhan, Peoples R China 9.Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Collaborat Innovat Ctr Canc Personalized Med, Nanjing, Peoples R China 10.Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
推荐引用方式 GB/T 7714	Song, Yuqin,Gao, Quanli,Zhang, Huilai,et al. Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study.[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39.
APA	Song, Yuqin.,Gao, Quanli.,Zhang, Huilai.,Fan, Lei.,Zhou, Jianfeng.,...&Zhu, Jun.(2021).Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study..JOURNAL OF CLINICAL ONCOLOGY,39.
MLA	Song, Yuqin,et al."Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study.".JOURNAL OF CLINICAL ONCOLOGY 39(2021).